Assessing amyloid PET positivity and cognitive function in Down syndrome to guide clinical trials targeting amyloid.

ABSTRACT:

Introduction

Trisomy 21, or Down syndrome (DS), predisposes individuals to early-onset Alzheimer's disease (AD). While monoclonal antibodies (mAbs) targeting amyloid are approved for older AD patients, their efficacy in DS remains unexplored. This study examines amyloid positron emission tomography (PET) positivity (A+), memory function, and clinical status across ages in DS to guide mAb trial designs.

Methods

Cross-sectional data from the Alzheimer Biomarker Consortium-Down Syndrome (ABC-DS) was analyzed. PET amyloid beta in Centiloids classified amyloid status using various cutoffs. Episodic memory was assessed using the modified Cued Recall Test, and clinical status was determined through consensus processes.

Results

Four hundred nine DS adults (mean age = 44.83 ye

SUBMITTER: Krasny S 

PROVIDER: S-EPMC11350128 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature